Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25836975 | 0.91 | ALDH1A1 (0.48) | CXCR4NPC1ALDH1A1NR1H4SMPD1 | |
| SCHEMBL26034373 | 0.90 | NPC1 (0.49) | NPC1ALDH1A1NR1H4MAPTTP53 | |
| SCHEMBL25837267 | 0.90 | CXCR4 (0.49) | CXCR4NPC1ALDH1A1NR1H4SMPD1 | |
| SCHEMBL24340636 | 0.89 | NPC1 (0.62) | CXCR4NPC1ALDH1A1MAPTTP53 | |
| SCHEMBL24340750 | 0.89 | CXCR4 (0.52) | CXCR4NPC1ALDH1A1MAPTTP53 | |
| SCHEMBL25855965 | 0.88 | CXCR4 (0.47) | CXCR4NPC1ALDH1A1NR1H4SMPD1 | |
| SCHEMBL25856862 | 0.86 | NPC1 (0.49) | NPC1ALDH1A1NR1H4SMPD1RAB9A | |
| SCHEMBL25851802 | 0.86 | ALDH1A1 (0.46) | CXCR4NPC1ALDH1A1NR1H4SMPD1 | |
| SCHEMBL26036435 | 0.85 | NPC1 (0.48) | NPC1NR1H4SMPD1MAPTRAB9A | |
| SCHEMBL25837270 | 0.85 | MAPT (0.51) | CXCR4NPC1ALDH1A1NR1H4SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | CXCR4 3027/4885NPC1 561/4885ALDH1A1 1330/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | CXCR4 609/4885NPC1 3878/4885ALDH1A1 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.